Compare HOG & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOG | SRPT |
|---|---|---|
| Founded | 1903 | 1980 |
| Country | United States | United States |
| Employees | 6400 | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 1994 | 2000 |
| Metric | HOG | SRPT |
|---|---|---|
| Price | $24.25 | $17.64 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 7 | 29 |
| Target Price | $24.00 | ★ $25.85 |
| AVG Volume (30 Days) | ★ 2.7M | 2.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.22 | ★ 2.88 |
| Revenue | ★ $4,473,175,000.00 | $2,198,237,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.79 | N/A |
| P/E Ratio | $109.59 | ★ $5.99 |
| Revenue Growth | N/A | ★ 15.58 |
| 52 Week Low | $17.09 | $10.42 |
| 52 Week High | $31.25 | $43.92 |
| Indicator | HOG | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.18 | 42.49 |
| Support Level | $22.36 | $17.11 |
| Resistance Level | $24.83 | $18.10 |
| Average True Range (ATR) | 0.96 | 0.77 |
| MACD | -0.19 | -0.09 |
| Stochastic Oscillator | 40.09 | 28.85 |
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring categories, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model, into electric with the LiveWire brand, and is returning to smaller-displacement bikes with the Sprint. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 34% of the heavyweight domestic market in 2025.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.